Nuvectis Pharma | Investor Presentation Deck | 23 slides · page 9 of 23
The slide demonstrates superior tumor volume reduction by NXP800 compared to standard-of-care Cisplatin in both SKOV-3 and TOV-21G models.
Pitch deck · traction · show_traction · dense density
Slide locked Sign in to view
Slide schematic 6/6
chart 2/2 source-note 1/1 table 1/1 title 2/2
Components 6
line line source-note data action-title headline
Tools 0
∅
No tools
No canon tool match is anchored to this slide.
Metrics 0
∅
No metrics
No metric insight is anchored to this slide.
Frameworks 0
∅
No frameworks
No framework match is anchored to this slide.